OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Non-small cell lung cancer

EGFR, ALK, KRAS G12C and the ADC wave in first and later lines.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 14:57 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:25 UTC.

Phase advances
9
since 2026-07-14
New Ph2+ trials
42
Results posted
6
Readouts due
22
primary completion reached
Trial papers
40
PubMed, last 60 days
  1. Results posted
    Results posted: NCT06083454

    Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

  2. New trial
    New Ph1 trial: NCT07928258

    Eli Lilly and Company. A Study of LY4336619 in Adult Participants With Advanced Solid Tumors

  3. Paper
  4. Results posted
    Results posted: SKYSCRAPER-01 (NCT04294810)

    A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  5. New trial
    New Ph1 trial: NCT07920822

    Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors

  6. Paper
  7. Paper
  8. New trial
    New Ph2 trial: NCT07917767

    Tang-Du Hospital. A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small Cell Lung Cancer

  9. New trial
    New Ph2 trial: NCT07919691

    Ruijin Hospital. Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy

  10. Paper
    Soxataltinib, a highly selective CNS-penetrant RET inhibitor demonstrates durable activity in RET fusion-positive non-small cell lung cancer phase 2 study.

    Xiong A, Meng X, Li X et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

    Publisher page
  11. Paper
  12. Results posted
    Results posted: NCT05553834

    PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

  13. Paper
  14. New trial
    New Ph1 trial: NCT07912268

    Jiangsu Simcere Pharmaceutical Co., Ltd.. Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  15. New trial
    New Ph1/Ph2 trial: NCT07912593

    Ensem Therapeutics. Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors

  16. Paper
  17. Phase advance
    Rescue Medications advances to Ph3 (indication level)

    Merck Sharp & Dohme LLC posted NCT07908537: A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)

  18. New trial
    New Ph1 trial: NCT07910942

    Kanvas Biosciences. A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer

  19. New trial
    New Ph1/Ph2 trial: APOLLO (NCT07909031)

    Crescent Biopharma, Inc.. CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

  20. New trial
    New Ph3 trial: ES-SPARE (NCT07908732)

    Ruijin Hospital. Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer

  21. New trial
    New Ph3 trial: NCT07908745

    Ruijin Hospital. Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC

  22. New trial
    New Ph2 trial: NCT07911449

    Cho Ray Hospital. Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases

  23. New trial
    New Ph3 trial: NCT07908537

    Merck Sharp & Dohme LLC. A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)

  24. Paper
  25. Paper
  26. Paper
  27. Readout due
    Readout due: NCT07647094 reached primary completion

    People's Hospital of Quzhou. A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer

  28. Results posted
    Results posted: NCT06171789

    PRO1107 in Patients With Advanced Solid Tumors

  29. Results posted
    Results posted: NCT04165083

    KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

  30. New trial
    New Ph1 trial: NCT07903415

    Pfizer. A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

  31. New trial
    New Ph1/Ph2 trial: NCT07902921

    National Cancer Institute (NCI). STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  32. New trial
    New Ph1 trial: NCT07899801

    M.D. Anderson Cancer Center. A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)

  33. Phase advance
    ERAS-0015 advances to Ph1/Ph2 (indication level)

    Tango Therapeutics, Inc. posted NCT07897734: TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients

  34. Readout due
    Readout due: TRITON reached primary completion

    AstraZeneca. A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

  35. New trial
    New Ph3 trial: NCT07897188

    Jiangsu Aosaikang Pharmaceutical Co., Ltd.. ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

  36. New trial
    New Ph1/Ph2 trial: NCT07897734

    Tango Therapeutics, Inc.. TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients

  37. New trial
    New Ph1 trial: NCT07899086

    Hansoh BioMedical R&D Company. A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer

  38. Phase advance
    Adebrelimab Injection advances to Ph3 (indication level)

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. posted NCT07896005: A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer

  39. Readout due
    Readout due: NCT05565378 reached primary completion

    GlaxoSmithKline. A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

  40. Phase advance
    adebrelimab advances to Ph3 in Neoadjuvant or perioperative (segment level)

    West China Hospital posted NCT07895238: A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC

  41. New trial
    New Ph3 trial: NCT07895238

    West China Hospital. A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC

  42. New trial
    New Ph2 trial: NCT07894367

    Peking University Cancer Hospital & Institute. Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study

  43. New trial
    New Ph1 trial: NCT07894874

    InventisBio Yiqi Beijing Limited. A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.

  44. New trial
    New Ph3 trial: NCT07896005

    Suzhou Suncadia Biopharmaceuticals Co., Ltd.. A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer

  45. New trial
    New Ph3 trial: NCT07895992

    Suzhou Suncadia Biopharmaceuticals Co., Ltd.. SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study

  46. Paper
  47. New trial
    New Ph1 trial: NCT07890246

    Immunome, Inc.. A Phase 1 Study of IM-1340 in Participants With Advanced Cancer

  48. New trial
    New Ph2 trial: NCT07890636

    Ruijin Hospital. Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC

  49. New trial
    New Ph1/Ph2 trial: NCT07890714

    Daiichi Sankyo. A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]

  50. New trial
    New Ph2 trial: LUNA-2 (NCT07890493)

    Canadian Cancer Trials Group. Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer

  51. New trial
    New Ph2/Ph3 trial: REACH (NCT07888075)

    AVEO Pharmaceuticals, Inc.. Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC

  52. New trial
    New Ph1/Ph2 trial: TOCI (NCT07889232)

    VA Office of Research and Development. Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer

  53. New trial
    New Ph1 trial: BActinium-2 (NCT07887971)

    Aktis Oncology, Inc.. A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

  54. New trial
    New Ph1 trial: NeoBRIO (NCT07886229)

    Second Xiangya Hospital of Central South University. Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer

  55. New trial
    New Ph2 trial: NCT07885709

    Peking University People's Hospital. MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC

  56. Readout due
    Readout due: NCT03999710 reached primary completion

    Memorial Sloan Kettering Cancer Center. Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

  57. New trial
    New Ph2 trial: NCT07882940

    Sun Yat-sen University. Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC

  58. New trial
    New Ph3 trial: IFEM (NCT07877584)

    German Cancer Research Center. PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%

  59. New trial
    New Ph2 trial: NCT07878871

    Hunan Province Tumor Hospital. Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study

  60. Paper
  61. New trial
    New Ph2 trial: OCEAN (NCT07874490)

    NYU Langone Health. Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

  62. New trial
    New Ph2 trial: NCT07874984

    Shenyang Sunshine Pharmaceutical Co., LTD.. SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer

  63. New trial
    New Ph2 trial: ILDR-ICI-LM (NCT07875465)

    Bing Xia. Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases

  64. Results posted
    Results posted: NCT05617313

    Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

  65. New trial
    New Ph2 trial: NCT07874464

    Sun Yat-sen University. Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC

  66. New trial
    New Ph1/Ph2 trial: NCT07873450

    Full-Life Technologies UK Limited. SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

  67. New trial
    New Ph2 trial: NCT07874282

    RemeGen Co., Ltd.. Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer

  68. New trial
    New Ph2 trial: NCT07871214

    Bristol-Myers Squibb. A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

  69. Paper
  70. Readout due
    Readout due: NCT05607550 reached primary completion

    ArriVent BioPharma, Inc.. Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

  71. Paper
  72. Readout due
    Readout due: NCT04332367 reached primary completion

    Abramson Cancer Center at Penn Medicine. Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

  73. Readout due
    Readout due: NCT04868877 reached primary completion

    Merus B.V.. Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  74. Readout due
    Readout due: NCT03122717 reached primary completion

    Dana-Farber Cancer Institute. Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

  75. Readout due
    Readout due: NCT05215548 reached primary completion

    National Taiwan University Hospital. Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

  76. Readout due
    Readout due: NCT05879822 reached primary completion

    Incyte Corporation. A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  77. Phase advance
    Zanzalintinib advances to Ph2 (indication level)

    Exelixis posted STELLAR-202: Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

  78. Readout due
    Readout due: NCT02716116 reached primary completion

    Takeda. A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

  79. Readout due
    Readout due: KontRASt-03 reached primary completion

    Novartis Pharmaceuticals. Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

  80. Readout due
    Readout due: AIVAA reached primary completion

    The Canadian College of Naturopathic Medicine. Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

  81. Readout due
    Readout due: NCT05845671 reached primary completion

    University of Colorado, Denver. Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

  82. Readout due
    Readout due: NCT04129502 reached primary completion

    Takeda. TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  83. Readout due
    Readout due: ARC-10 reached primary completion

    Arcus Biosciences, Inc.. Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

  84. Readout due
    Readout due: NCT05017025 reached primary completion

    M.D. Anderson Cancer Center. Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

  85. Paper
  86. Readout due
    Readout due: KontRASt-02 reached primary completion

    Novartis Pharmaceuticals. Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  87. Readout due
    Readout due: NCT05816252 reached primary completion

    Klus Pharma Inc.. A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

  88. Readout due
    Readout due: LUCAS reached primary completion

    Yonsei University. Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

  89. Phase advance
    zoldonrasib advances to Ph3 (indication level)

    Revolution Medicines, Inc. posted RASolve 308: Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

  90. Readout due
    Readout due: eVOLVE-Lung02 reached primary completion

    AstraZeneca. A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

  91. Readout due
    Readout due: G360-IIT reached primary completion

    Hackensack Meridian Health. Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

  92. Phase advance
    BL-B01D1 advances to Ph2/Ph3 (indication level)

    Sichuan Baili Pharmaceutical Co., Ltd. posted NCT07739186: A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)

  93. Phase advance
    Oxaliplatin advances to Ph1/Ph2 (indication level)

    Astellas Pharma Global Development, Inc. posted NCT07730021: A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

  94. Phase advance
    5-fluorouracil advances to Ph1/Ph2 (indication level)

    Astellas Pharma Global Development, Inc. posted NCT07730021: A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.